Qiagen stock
Price history
+8.56% over the period1 year: from €41.52 (November 20, 2025) to €45.07 (November 20, 2026), +8.56%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €45.07 |
| October 30, 2026 | €45.09 |
| September 30, 2026 | €38.72 |
| August 31, 2026 | €37.24 |
| July 31, 2026 | €35.72 |
| June 30, 2026 | €33.90 |
| May 29, 2026 | €31.65 |
| April 30, 2026 | €29.03 |
| March 31, 2026 | €34.74 |
| February 27, 2026 | €41.96 |
| January 30, 2026 | €44.62 |
| December 30, 2025 | €40.90 |
| November 28, 2025 | €43.29 |
| November 20, 2025 | €41.52 |
At a glance
The company
Provide sample-to-insight solutions that transform biological samples into molecular insights through consumables and instruments for diagnostics and life sciences
Latest results
Quarter to September 30, 2026 · EPS $0.51 (estimate $0.54)
Next event
TickerLandia's take on Qiagen
- Priced in line with similar companies: trailing 12-month P/E 29 vs 30 (−4%) in a group of 11.
- Strong point: Market momentum (84/100 in its group). Weak point: Growth (16/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.31% from the 52-week high
Analysts · 5 analysts
Average target€43.10−4.37% vs. price
Buy 1 · Hold 4 · Sell 0
TickerLandia Fingerprint: Qiagen
Compared with similar companies: very strong momentum and very low growth.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow38
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 28.5 27 Forward P/E 19.5 46 EV/EBITDA 13.5 34 Price/book 3.01 37 Price/sales 4.40 46 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 67.0% 87 Operating margin 26.7% 83 Net margin 18.2% 72 ROE 10.8% 37 ROA 5.7% 50 Earnings stabilityhigh65
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.4% 69 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthvery low16
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −19.20% 6 Revenue growth (year over year) +2.90% 20 Average revenue growth (3 years) −0.81% 20 Financial strengthhigh73
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.47 65 Current ratio 2.63 83 Net debt/EBITDAcounts in reverse: lower means more financial strength 1.37 66 Interest coverage 16.6 79 Dividendaverage45
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.7% 23 Payout ratiopays out more than its earnings 143.4% 91 Consecutive dividend years 3 years 21 Market momentumvery strong84
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +21.89% 95 Distance from 200-day average +22.44% 95 Relative strength (6 months) +50.29% 98 1-year return +8.56% 50 Riskaverage43
How much the price swings.
Metric Value Position in group Volatility (60 days) 22.9% 30 Beta (1 year) 0.32 14 Maximum drawdown (12 months) 39.4% 85
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Qiagen is in line with similar companies
Qiagen's P/E (trailing 12 months): 28.5, in line with the median of a group of 11 similar companies (29.6).
Compared with 11 similar companies
| Metric | Qiagen | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 28.5 | Middle | |
| Forward P/E | 19.5 | Middle | |
| Operating margin | 26.7% | High | |
| ROE | 10.8% | Middle | |
| Debt/equity | 0.47 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Qiagen. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$547.87M
Latest quarter · Q3 2026
Net income
$105.66M
Latest quarter · Q3 2026
Quarterly net margin
19.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €9.31B
- P/E
- 28.5
- EPS
- €1.58
- Volume
- 958.3K
- Daily trading
- €46.6M
- Dividend yield
- 0.68%
- Last ex-dividend on July 7, 2026
How Qiagen is changing
All resultsRevenue grew 2.2% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 147% of net income
Returns
Qiagen returns with dividends
€1,000 invested in Qiagen 5 years ago, on November 22, 2021, would be worth €925 today with dividends reinvested: −7.51% in total, −1.55% per year. On price alone it would be €822 (−17.78%).
| Period | Qiagen | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | +5.23% | −1.98% | €1,052 |
| 6 months | +50.69% | +0.26% | €1,507 |
| Year to date | +10.20% | +1.28% | €1,102 |
| 1 year | +14.73% | +6.55% | €1,147 |
| 3 years | +25.40% | +55.98% | €1,254 |
| 5 years | −7.51% | +53.90% | €925 |
| 10 years | +73.40% | +132.12% | €1,734 |
Over the last 6 months it has done better than 87% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Qiagen: technical analysis
Qiagen is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 66.6% below its all-time closing high (€134.88, July 18, 2000).
- Trend
- Upward
- RSI (14 sessions)
- 69
- Between 30 and 70
- vs 200-session average
- +22.44%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 16, 2026
Support and resistance
Price areas where Qiagen has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€45.47+0.88%2 touches, last on November 12, 2026
- Last price€45.07
- Support€44.10−2.16%2 touches, last on February 13, 2026
- Support€42.07−6.65%3 touches, last on October 6, 2026
- Support€40.14−10.95%2 touches, last on February 23, 2026
Volatility and risk
Over the last year it has moved little with the DAX.
- Beta (1 year) vs DAX
- 0.32
- Volatility (60 sessions, annualised)
- 22.9%
- Largest fall in the last year
- −39.45%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Qiagen: seasonality
Average monthly price change over 29 years
Over the last 29 years, the strongest month for Qiagen has been November: +4.72% on average, positive in 20 years out of 28. The weakest has been March: −2.75% on average, positive in 8 years out of 28.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.39% | +2.43% | 16 of 28 |
| February | +3.67% | +1.16% | 16 of 28 |
| March | −2.75% | −1.02% | 8 of 28 |
| April | +0.67% | +1.29% | 15 of 28 |
| May | +1.02% | +0.12% | 14 of 28 |
| June | −0.58% | +0.62% | 15 of 28 |
| July | +1.82% | +3.57% | 17 of 28 |
| August | −0.86% | −1.08% | 12 of 29 |
| September | −2.47% | −2.25% | 11 of 29 |
| October | +2.81% | +0.16% | 15 of 29 |
| November | +4.72% | +3.01% | 20 of 28 |
| December | −1.17% | −0.28% | 12 of 28 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Qiagen and its competitors
Laboratories in molecular diagnostics and life sciences research worldwide use the products of Qiagen N.V., which turns biological samples into molecular insights. Its range covers sample technology consumables such as nucleic acid purification kits and instruments, assays for infectious disease, oncology and sexual and reproductive health testing, research PCR and digital PCR solutions, NGS gene panels and library prep kits, DNA methylation analysis, human ID and forensics assays, and bioinformatics software delivered as a service.
- Headquarters
- Venlo, Netherlands
- Employees
- 5,400
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| QiagenQIA | $10.23B | 26.7% | 28.5 | +50.69% |
| bioMérieuxBIM | $11.82B | 16.0% | 23.4 | +25.67% |
| Eurofins ScientificERF | $16.03B | 14.1% | 29.6 | +37.31% |
| DiaSorinDIA | $4.21B | 22.3% | 28.6 | +14.88% |
| Lonza GroupLONN | $54.2B | 23.5% | 43.2 | +32.22% |
| DiagnostykaDIA | $1.27B | 14.9% | 20.2 | −6.62% |
Same industry or related industries, similar size. Compare Qiagen with its competitors · Full profile
